NDAINJECTIONINJECTABLE
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
3
Data completeness
4/8 — Partial
ANTIZOL (fomepizole) by R-Pharm US is clinical pharmacology mechanism of action: antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. First approved in 1997.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Antizol (fomepizole) is a small-molecule competitive inhibitor of alcohol dehydrogenase used to treat acute poisoning from ethylene glycol and methanol. It blocks the toxic metabolic conversion of these poisons to their lethal byproducts (oxalate from ethylene glycol, formic acid from methanol), preventing metabolic acidosis and organ damage. The drug is administered intravenously as an antidote in emergency and critical care settings.
LOE Approaching9mo to LOE
As LOE approaches in 2027, the brand team is likely consolidating to support transition planning; expect stable but limited headcount growth focused on market protection.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action: Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to…
Worked on ANTIZOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.